HDAC3 and acute myeloid leukemia: The results indicated that HDAC3 depletion in BMSCs resulted in significant antitumor activity in vivo, leading to reduced AML growth over 24 days (Fig. 7E–H), supporting our in vitro findings that HDAC3 silencing in BMSCs inhibits AML cell proliferation.